as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,449.9
Change
+5.2 (0.36%)
Open
₹1,448.0
Prev. Close
₹1,444.7
Day High
₹1,467.7
Day Low
₹1,441.5
Volume Analysis
Traded
211,425
Delivered
130,295
Delivery %
61.63%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (31.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,490.76 | ₹1,479.23 | ₹1,464.56 | ₹1,453.03 | ₹1,438.36 | ₹1,426.83 | ₹1,412.16 |
| Fibonacci | ₹1,479.23 | ₹1,469.22 | ₹1,463.04 | ₹1,453.03 | ₹1,443.02 | ₹1,436.84 | ₹1,426.83 |
| Camarilla | ₹1,457.11 | ₹1,454.7 | ₹1,452.3 | ₹1,453.03 | ₹1,447.5 | ₹1,445.1 | ₹1,442.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+59.75%
1 Week
+0.43%
1 Month
+15.26%
3 Months
+7.33%
6 Months
+39.55%
1 Year
+59.35%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Market Cap
₹17,803 Cr
P/E (TTM)
50.6
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Alivus Life Sciences Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (31.0%); promoter holding is falling. FII holding has been rising.
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
On November 11, 2026, Alivus acquired 65.01% of IQGEN-X Pharma; remaining stake to be acquired.
Alivus executed SHA for 76% IQGEN-X stake, with option to acquire remaining 24% in five years.
Nirma sold 36.8 lakh Alivus shares on 6 Nov, cutting holding to 71.74%.
Please find attached herewith submission with respect to transcript of the earning call.
Alivus Life Sciences schedules one-on-one investor meetings with Avarta Capital, BOI Mutual Fund and Bandhan Mutual Fund on Nov 6 and 12, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | 682 |
| Expenses + | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 | 417 |
| Operating Profit | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | 265 |
| OPM % | 28.0% | 30.0% | 26.0% | 27.0% | 27.0% | 30.0% | 31.0% | 29.0% | 30.0% | 34.0% | 31.0% | 33.0% | 39.0% |
| Other Income + | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 | 20 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 | 22 |
| Profit before tax | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | 262 |
| Tax % | 25.0% | 26.0% | 24.0% | 26.0% | 25.0% | 26.0% | 26.0% | 25.0% | 25.0% | 24.0% | 25.0% | 25.0% | 25.0% |
| Net Profit + | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | 197 |
| EPS in Rs | 10 | 10 | 8 | 9 | 8 | 11 | 12 | 10 | 11 | 12 | 13 | 13 | 16 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 17 | 6 | -14 | 2 | -15 | 12 | 21 | 2 | 16 | 5 | 6 | 6 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|
| Sales + | 0 | 886 | 1,537 | 1,885 |
| Expenses + | 0 | 639 | 1,065 | 1,294 |
| Operating Profit | 0 | 248 | 472 | 591 |
| OPM % | -4.0% | 28.0% | 31.0% | 31.0% |
| Other Income + | 0 | 0 | 12 | 1 |
| Interest | 0 | 1 | 34 | 88 |
| Depreciation | 0 | 19 | 29 | 33 |
| Profit before tax | 0 | 228 | 421 | 471 |
| Tax % | 4,200.0% | 14.0% | 26.0% | 25.0% |
| Net Profit + | 0 | 196 | 313 | 352 |
| EPS in Rs | 0 | 18 | 29 | 33 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | — | — | 73 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|
| Reserves | -1 | — | — | — |
| Borrowings + | 0 | — | — | — |
| Other Liabilities + | 1 | — | — | — |
| Total Liabilities | 0 | — | — | — |
| Fixed Assets + | 0 | — | — | — |
| CWIP | 0 | — | — | — |
| Investments | 0 | — | — | — |
| Other Assets + | 0 | — | — | — |
| Total Assets | 0 | — | — | — |
| Equity Capital | 0 | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | — | — | — |
| Cash from Investing Activity + | 0 | — | — | — |
| Cash from Financing Activity + | 0 | — | — | — |
| Net Cash Flow | 0 | — | — | — |
| Free Cash Flow | 0 | — | — | — |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 4,800 | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.84% | 10.73% | 10.76% | 12.99% | 13.4% | 13.25% | 13.03% | 12.79% | 12.89% | 12.55% | 12.42% | 12.19% |
| Promoters | 82.85% | 82.85% | 82.85% | 75.0% | 75.0% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% | 74.85% |
| FII | 4.57% | 5.01% | 4.81% | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.08% | 5.3% | 5.54% | 5.93% |
| DII | 0.74% | 1.41% | 1.57% | 4.16% | 4.86% | 5.19% | 5.62% | 5.47% | 7.13% | 7.27% | 7.18% | 7.03% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Alivus Life Sciences Ltd (this stock) | 17,803 | 50.6 | — | — |
| Caplin Point Lab Ltd. | 17,863 | 25.9 | 4.58 | 20.9% |
| Syngene International Ltd | 17,935 | 67.5 | 3.7 | 7.78% |
| Pfizer Ltd | 17,601 | 115.0 | 12.74 | 19.8% |
| Cohance Lifesciences Ltd | 17,511 | 359.0 | 4.49 | 4.89% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
| Eris Lifesciences Limited | 18,448 | 24.7 | 4.45 | 18.7% |
Which Mutual Funds Hold Alivus Life Sciences Ltd?
Frequently Asked Questions about Alivus Life Sciences Ltd
Alivus Life Sciences Ltd (ALIVUS) closed at ₹1,449.9 on NSE on 19 November 2026, up 5.2 (0.36%) from the previous close.
Alivus Life Sciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol ALIVUS.
Alivus Life Sciences Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 50.6.
Alivus Life Sciences Ltd has a dividend yield of 0.35%.
Alivus Life Sciences Ltd's 52-week high is ₹1,574.0 and its 52-week low is ₹819.0.
Alivus Life Sciences Ltd has a market capitalisation of ₹17,803 crore.
Alivus Life Sciences Ltd has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Alivus Life Sciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.